Health care stocks were edging higher premarket Thursday, with the iShares Biotechnology ETF (IBB) and The Health Care Select Sector SPDR Fund (XLV) up 0.6%.
Neumora Therapeutics (NMRA) shares were down more than 82% after the company said that the phase 3 KOASTAL-1 study of navacaprant in treating major depressive disorder failed to meet its primary endpoint.
Hutchmed (China) (HCM) shares were up more than 5% after the company said overnight that the China National Medical Products Administration has accepted and granted priority review to its New Drug Application for the combination of Orpathys and Tagrisso for the treatment of patients with a specific type of non-small cell lung cancer.
ANI Pharmaceuticals (ANIP) shares were up over 4% after the company said it has launched its prucalopride tablets, the generic version of Motegrity, after receiving final approval from the US Food and Drug Administration.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。